Abstract
Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30 and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.
Original language | English |
---|---|
Article number | 613980 |
Journal | International Journal of Surgical Oncology |
Volume | 2012 |
DOIs | |
Publication status | Published - 2012 |
ASJC Scopus subject areas
- Oncology
- Surgery